Clinical Trial Update: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tamoxifen citrate, letrozole, anastrozole, or exemestane with or without chemotherapy in invasive breast cancer (RxPONDER) is active/no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ductal Carcinoma in Situ
• Invasive Breast Carcinoma
• Multicentric Breast Carcinoma
• Multifocal Breast Carcinoma
• Synchronous Bilateral Breast Carcinoma

Drugs mentioned

• Anastrozole (Anastrozole)
• Exemestane (Exemestane)
• Letrozole (letrozole)
• Tamoxifen citrate (tamoxifen citrate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-06-27